Navigation Links
Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
Date:9/25/2013

C clinical trial," said Dr. Colin Hislop, Anthera's Chief Medical Officer. "The pathology of IgA nephropathy is heavily centered on the abundance of these proteins."

Oral Presentation: "Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Serum Immunoglobulins and Infection Risk in Patients with Systemic Lupus Erythematosus: Observations from the Placebo-Controlled PEARL-SC and Open-Label Extension Studies": Clinical Aspects and Treatment: Biologic Therapy (2:30PM-4:00PM, October 28th)

Poster: "Effects of Chronic Treatment with Blisibimod, an Inhibitor of B Cell Activating Factor, on Renal and Inflammation Biomarkers in Patients with Systemic Lupus Erythematosus: Observations from the Placebo-Controlled PEARL-SC and Open-Label Extension Studies": Clinical Aspects Poster II: Central Nervous System Manifestation (8:30AM – 4:00PM, October 28th)

Anthera will be hosting a breakout session following the presentations by Dr. Furie. Please contact ir@anthera.com for the event details.

About Blisibimod and PEARL-SC

Anthera is developing blisibimod, a selective inhibitor of B-cell activating factor (BAFF), to explore its clinical utility in various autoimmune diseases including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod is a novel fusion protein, or peptibody, and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications. BAFF, also known as BLyS (B lymphocyte stimulator), is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. B-cells represent a critical component of human immune response to infection and other pathogens.  However, abnormal elevations of B-cells and BAFF may lead to an overactive immune response which may damage normal healthy tissues and organ systems. Multiple clinical st
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
2. Anthera Announces Initiation of BRIGHT-SC Phase 2 Clinical Study in IgA Nephropathy with Blisibimod
3. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
4. Anthera Pharmaceuticals Announces Personnel Changes
5. Anthera Pharmaceuticals to Present at Annual Jefferies Healthcare Conference
6. Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
7. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
8. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
9. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
11. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
...   Sysmex America, Inc., a global leader in medical ... its 200th placement of Sysmex WAM ™ ... WAM is now connecting nearly 600 sites and approximately ... Canada. Sysmex WAM plays a key role in delivering ...
... March 20, 2012   A new Consumer Reports poll shows ... The poll was released just as House and Senate ... governing medical devices and at a time when the ... intense criticism.  The House Energy and ...
Cached Medicine Technology:Sysmex America Achieves Clinical Laboratory Connectivity Milestone 2Consumer Reports Poll: Americans Overwhelmingly Support Strong Medical Device Safety Oversight 2Consumer Reports Poll: Americans Overwhelmingly Support Strong Medical Device Safety Oversight 3Consumer Reports Poll: Americans Overwhelmingly Support Strong Medical Device Safety Oversight 4
(Date:4/24/2014)... detailed atlas with environment and health maps at a ... by the UK Small Area Health Statistics Unit (SAHSU), ... based at Imperial College London, the open-access atlas allows ... study the geographical pattern of 14 diseases and conditions ... and low birth weight. Alongside this it provides maps ...
(Date:4/24/2014)... have identified a way to sensitise cancer cells to ... The study published today in Cell Reports , ... to target cells that have become resistant to treatment. ... the possible mechanisms behind resistance to chemotherapy drugs like ... , Dr Andrew Gilmore, who led the research team ...
(Date:4/24/2014)... April 24, 2014 ,Take me out to the ... and kale chips. The more likely culprits include French ... , Unfortunately for children who play youth baseball, eating ... to weight problems, according to researchers at Wake Forest ... online edition of Childhood Obesity , found that ...
(Date:4/24/2014)... aspects, the corresponding terminology, and the relevance of ... in publications on randomized controlled trials (RCTs). This ... German Institute for Quality and Efficiency in Health ... final report. , Together with external experts, IQWiG ... glioblastoma, lung cancer, malignant melanoma, and pancreatic cancer. ...
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
Breaking Medicine News(10 mins):Health News:New high-detail atlas offers tool to explore local environment and health 2Health News:New high-detail atlas offers tool to explore local environment and health 3Health News:Scientists find way to target cells resistant to chemo 2Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
... 2, 2010 With the mutual goal of ... Pharmacopeial Convention (USP) and the Ukraine Scientific Pharmacopoeial ... have entered into an agreement to share standards ... medicines. Specifically, the Centre will have a five-year, ...
... (Zometa) can help fight metastatic breast cancer when given before ... St. Louis. When the drug was given along with ... the number of women who had tumor cells in their ... was published in the May issue of The Lancet ...
... In the largest study to date of a rare and ... in Detroit found radiation therapy may not improve a patient,s ... the bladder was poor, the study revealed several factors that ... 60 or younger, and having cystectomy, a procedure that either ...
... The current problems of access, affordability and quality in ... health insurance to all. The editors of the new ... propose an engineering approach to healthcare. In this publication ... A. Cortese and a team of highly regarded thought ...
... at age 40 in this group , WEDNESDAY, June 2 ... at higher risk of developing prostate cancer than white men, ... to be more likely to develop aggressive forms of the ... blacks and 64 whites -- whose prostates were removed at ...
... ... repository in IHE , ... Shawnee, Kan. (Vocus) -- Perceptive Software , creator of enterprise content management ... (IHE) Connectathon, held in Boardeaux, France., , , , ,IHE is an initiative by ...
Cached Medicine News:Health News:US, Ukraine agree to share standards for quality of medicines 2Health News:Bone drug suppresses wandering tumor cells in breast cancer patients 2Health News:Radiation does not improve survival for rare, invasive bladder cancer 2Health News:Perceptive Software Announces Successful Participation in Integrating the Healthcare Enterprise (IHE) Connectathon 2
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
Medicine Products: